{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:35:30Z","timestamp":1789011330005,"version":"build-2803163510"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":257,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Histiocytic and dendritic cell neoplasms are a diverse group of tumors arising from monocytic or dendritic cell lineage. Whereas the genomic features for Langerhans cell histiocytosis and Erdheim-Chester disease have been well described, other less common and often aggressive tumors in this broad category remain poorly characterized, and comparison studies across the World Health Organization diagnostic categories are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tumor samples from a total of 102 patient cases within four major subtypes of malignant histiocytic and dendritic cell neoplasms, including 44 follicular dendritic cell sarcomas (FDCSs), 41 histiocytic sarcomas (HSs), 7 interdigitating dendritic cell sarcomas (IDCSs), and 10 Langerhans cell sarcomas (LCSs), underwent hybridization capture with analysis of up to 406 cancer-related genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the entire cohort of 102 patients, CDKN2A mutations were most frequent across subtypes and made up 32% of cases, followed by TP53 mutations (22%). Mitogen-activated protein kinase (MAPK) pathway mutations were present and enriched among the malignant histiocytosis (M) group (HS, IDCS, and LCS) but absent in FDCS (72% vs. 0%; p &amp;lt; .0001). In contrast, NF-\u03baB pathway mutations were frequent in FDCSs but rare in M group histiocytoses (61% vs. 12%; p &amp;lt; .0001). Tumor mutational burden was significantly higher in M group histiocytoses as compared with FDCSs (median 4.0\/Mb vs. 2.4\/Mb; p = .012). We also describe a pediatric patient with recurrent secondary histiocytic sarcoma treated with targeted therapy and interrogated by molecular analysis to identify mechanisms of therapeutic resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A total of 42 patient tumors (41%) harbored pathogenic mutations that were potentially targetable by approved and\/or investigative therapies. Our findings highlight the potential value of molecular testing to enable precise tumor classification, identify candidate oncogenic drivers, and define personalized therapeutic options for patients with these aggressive tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>This study presents comprehensive genomic profiling results on 102 patient cases within four major subtypes of malignant histiocytic and dendritic cell neoplasms, including 44 follicular dendritic cell sarcomas (FDCSs), 41 histiocytic sarcomas (HSs), 7 interdigitating dendritic cell sarcomas (IDCSs), and 10 Langerhans cell sarcomas (LCSs). MAPK pathway mutations were present and enriched among the malignant histiocytosis (M) group (HS, IDCS, and LCS) but absent in FDCSs. In contrast, NF-\u03baB pathway mutations were frequent in FDCSs but rare in M group histiocytosis. A total of 42 patient tumors (41%) harbored pathogenic mutations that were potentially targetable by approved and\/or investigative therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13801","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T16:32:34Z","timestamp":1619541154000},"page":"e1263-e1272","source":"Crossref","is-referenced-by-count":64,"title":["Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma"],"prefix":"10.1093","volume":"26","author":[{"given":"Lucas R.","family":"Massoth","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin P.","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Ferry","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nardi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Petur","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Sadigh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Venkataraman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Selig","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Friedmann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Samore","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Keith","family":"Killian","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7964-0718","authenticated-orcid":false,"given":"Riza","family":"Milante","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jose R. Reyes Memorial Medical Center, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Giessinger","sequence":"additional","affiliation":[{"name":"A.T. Still University School of Osteopathic Medicine, Mesa, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Foley-Peres","sequence":"additional","affiliation":[{"name":"Department of Biology, Bristol Community College, Fall River, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Marcus","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Severson","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Duncan","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smruthy","family":"Sivakumar","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"},{"name":"Department of Pathology, State University of New York Upstate Medical University, Syracuse, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Desphande","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakti H.","family":"Ramkissoon","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"},{"name":"Wake Forest Comprehensive Cancer Center and Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Anne","family":"Vergilio","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abner","family":"Louissaint","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence R.","family":"Zukerberg","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9190-2450","authenticated-orcid":false,"given":"Erik A.","family":"Williams","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"},{"name":"Department of Pathology, Department of Dermatology, UCSF Dermatopathology Service, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"2022020214134257000_onco13801-bib-0001","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017","edition":"4th ed."},{"key":"2022020214134257000_onco13801-bib-0002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11912-019-0810-6","article-title":"Systemic histiocytosis (Langerhans cell histiocytosis, Erdheim\u2013Chester disease, Destombes\u2013Rosai\u2013Dorfman disease): From oncogenic mutations to inflammatory disorders","volume":"21","author":"Papo","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2022020214134257000_onco13801-bib-0003","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"key":"2022020214134257000_onco13801-bib-0004","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","article-title":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","volume":"25","author":"Durham","year":"2019","journal-title":"Nat Med"},{"key":"2022020214134257000_onco13801-bib-0005","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"key":"2022020214134257000_onco13801-bib-0006","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2022020214134257000_onco13801-bib-0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005965","article-title":"A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal","volume":"14","author":"Sun","year":"2018","journal-title":"PLoS Comput Biol"},{"key":"2022020214134257000_onco13801-bib-0008","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2022020214134257000_onco13801-bib-0009","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"key":"2022020214134257000_onco13801-bib-0010","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"key":"2022020214134257000_onco13801-bib-0011","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1200\/PO.19.00288","article-title":"Pan-cancer landscape analysis reveals recurrent KMT2A-MAML2 gene fusion in aggressive histologic subtypes of thymoma","volume":"4","author":"Massoth","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2022020214134257000_onco13801-bib-0012","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jmoldx.2016.10.007","article-title":"Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: Molecular analysis for therapy choice clinical trial","volume":"19","author":"Lih","year":"2017","journal-title":"J Mol Diagnostics"},{"key":"2022020214134257000_onco13801-bib-0013","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41379-018-0200-x","article-title":"Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma","volume":"32","author":"Shanmugam","year":"2019","journal-title":"Mod Pathol"},{"key":"2022020214134257000_onco13801-bib-0014","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2022020214134257000_onco13801-bib-0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"2022020214134257000_onco13801-bib-0016","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41375-018-0323-6","article-title":"Recurrent PDGFRB mutations in unicentric Castleman disease","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"key":"2022020214134257000_onco13801-bib-0017","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3324\/haematol.2018.204974","article-title":"Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort","volume":"104","author":"Zaliova","year":"2019","journal-title":"Haematologica"},{"key":"2022020214134257000_onco13801-bib-0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pbc.28200","article-title":"Secondary histiocytic sarcoma with BRAFV600E mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib","volume":"67","author":"Venkataraman","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2022020214134257000_onco13801-bib-0019","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/01.pas.0000131541.95394.23","article-title":"Extranodal histiocytic sarcoma: Clinicopathologic analysis of 14 cases of a rare epithelioid malignancy","volume":"28","author":"Hornick","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"2022020214134257000_onco13801-bib-0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.critrevonc.2013.05.006","article-title":"Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series","volume":"88","author":"Saygin","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"2022020214134257000_onco13801-bib-0021","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ejca.2015.06.109","article-title":"Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas","volume":"51","author":"Gounder","year":"2015","journal-title":"Eur J Cancer"},{"key":"2022020214134257000_onco13801-bib-0022","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.clml.2019.03.026","article-title":"Incidence, Clinical features, and outcomes of Langerhans cell sarcoma in the United States","volume":"19","author":"Tella","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022020214134257000_onco13801-bib-0023","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ctrv.2015.02.011","article-title":"Langerhans cell sarcoma: A systematic review","volume":"41","author":"Howard","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"2022020214134257000_onco13801-bib-0024","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bjh.14672","article-title":"Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma","volume":"178","author":"Jain","year":"2017","journal-title":"Br J Haematol"},{"key":"2022020214134257000_onco13801-bib-0025","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.5858\/arpa.2018-0220-RA","article-title":"Histiocytic sarcoma: Review, discussion of transformation from B-cell lymphoma, and differential diagnosis","volume":"142","author":"Skala","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"2022020214134257000_onco13801-bib-0026","doi-asserted-by":"crossref","first-page":"98723","DOI":"10.18632\/oncotarget.21920","article-title":"Prognostic factors for histiocytic and dendritic cell neoplasms","volume":"8","author":"Shimono","year":"2017","journal-title":"Oncotarget"},{"key":"2022020214134257000_onco13801-bib-0027","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/cncy.21851","article-title":"Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics","volume":"125","author":"Hung","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"2022020214134257000_onco13801-bib-0028","first-page":"378","article-title":"A case of interdigitating dendritic cell sarcoma\/histiocytic sarcoma - a diagnostic pitfall","volume":"7","author":"Johnson","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"2022020214134257000_onco13801-bib-0029","first-page":"827","article-title":"Histiocytic sarcoma with interdigitating dendritic cell differentiation","volume":"26","author":"Porter","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"2022020214134257000_onco13801-bib-0030","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/modpathol.3800346","article-title":"Histiocytic sarcoma: A study of five cases including the histiocyte marker CD163","volume":"18","author":"Vos","year":"2005","journal-title":"Mod Pathol"},{"key":"2022020214134257000_onco13801-bib-0031","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/ajcp\/100.3.285","article-title":"True histiocytic lymphoma of small intestine: Analysis of two S-100 protein-positive cases with features of interdigitating reticulum cell sarcoma","volume":"100","author":"Miettinen","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"2022020214134257000_onco13801-bib-0032","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/dc.21215","article-title":"Histiocytic sarcoma with interdigitating dendritic cell differentiation: A case report with fine needle aspiration cytology and review of literature","volume":"38","author":"Yang","year":"2010","journal-title":"Diagn Cytopathol"},{"key":"2022020214134257000_onco13801-bib-0033","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/bjh.16006","article-title":"Cyclin D1 expression and novel mutational findings in Rosai-Dorfman disease","volume":"186","author":"Baraban","year":"2019","journal-title":"Br J Haematol"},{"key":"2022020214134257000_onco13801-bib-0034","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89473","article-title":"Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes","volume":"2","author":"Lee","year":"2017","journal-title":"JCI Insight"},{"key":"2022020214134257000_onco13801-bib-0035","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semcdb.2018.03.002","article-title":"Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages","volume":"86","author":"Durham","year":"2019","journal-title":"Semin Cell Dev Biol"},{"key":"2022020214134257000_onco13801-bib-0036","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2016-08-733790","article-title":"Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis","volume":"128","author":"Chakraborty","year":"2016","journal-title":"Blood"},{"key":"2022020214134257000_onco13801-bib-0037","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/modpathol.2017.160","article-title":"The histopathology of Erdheim-Chester disease: A comprehensive review of a molecularly characterized cohort","volume":"31","author":"Ozkaya","year":"2018","journal-title":"Mod Pathol"},{"key":"2022020214134257000_onco13801-bib-0038","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/modpathol.2017.55","article-title":"Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease","volume":"30","author":"Garces","year":"2017","journal-title":"Mod Pathol"},{"key":"2022020214134257000_onco13801-bib-0039","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/modpathol.2017.34","article-title":"Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor suppressor-driven biology","volume":"30","author":"Andersen","year":"2017","journal-title":"Mod Pathol"},{"key":"2022020214134257000_onco13801-bib-0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/modpathol.2015.130","article-title":"Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-\u03baB regulatory genes","volume":"29","author":"Griffin","year":"2016","journal-title":"Mod Pathol"},{"key":"2022020214134257000_onco13801-bib-0041","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.it.2013.11.001","article-title":"Follicular dendritic cells: Origin, phenotype, and function in health and disease","volume":"35","author":"Aguzzi","year":"2014","journal-title":"Trends Immunol"},{"key":"2022020214134257000_onco13801-bib-0042","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1126\/science.1117729","article-title":"A clonogenic bone harrow progenitor specific for macrophages and dendritic cells","volume":"311","author":"Fogg","year":"2006","journal-title":"Science"},{"key":"2022020214134257000_onco13801-bib-0043","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/imm.12888","article-title":"Human dendritic cell subsets: An update","volume":"154","author":"Collin","year":"2018","journal-title":"Immunology"},{"key":"2022020214134257000_onco13801-bib-0044","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/imm.12117","article-title":"Human dendritic cell subsets","volume":"140","author":"Collin","year":"2013","journal-title":"Immunology"},{"key":"2022020214134257000_onco13801-bib-0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/his.12416","article-title":"Frequent detection of BRAFV600E mutations in histiocytic and dendritic cell neoplasms","volume":"65","author":"Go","year":"2014","journal-title":"Histopathology"},{"key":"2022020214134257000_onco13801-bib-0046","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3324\/haematol.2019.230375","article-title":"Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"key":"2022020214134257000_onco13801-bib-0047","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41379-020-00673-x","article-title":"The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy","volume":"34","author":"Egan","year":"2021","journal-title":"Mod Pathol"},{"key":"2022020214134257000_onco13801-bib-0048","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/annonc\/mdw299","article-title":"Sustained response to salvage therapy for dabrafenib-resistant metastatic Langerhans cell sarcoma","volume":"27","author":"Lorillon","year":"2016","journal-title":"Ann Oncol"},{"key":"2022020214134257000_onco13801-bib-0049","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1182\/blood-2015-06-650036","article-title":"Dramatic transient improvement of metastatic BRAFV600E-mutated Langerhans cell sarcoma under treatment with dabrafenib","volume":"126","author":"Mourah","year":"2015","journal-title":"Blood"},{"key":"2022020214134257000_onco13801-bib-0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13000-018-0758-0","article-title":"KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma","volume":"13","author":"Choi","year":"2018","journal-title":"Diagn Pathol"},{"key":"2022020214134257000_onco13801-bib-0051","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/PAS.0000000000000989","article-title":"CDKN2A\/B deletion and double-hit mutations of the MAPK pathway underlie the aggressive behavior of Langerhans cell tumors","volume":"42","author":"Xerri","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"2022020214134257000_onco13801-bib-0052","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdz125","article-title":"RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: A mechanism of resistance to BRAF inhibitor","volume":"30","author":"Jouenne","year":"2019","journal-title":"Ann Oncol"},{"key":"2022020214134257000_onco13801-bib-0053","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4103\/1947-2714.114172","article-title":"Langerhans cell sarcoma arising from chronic lymphocytic lymphoma\/small lymphocytic leukemia: Lineage analysis and BRAF V600E mutation study","volume":"5","author":"Chen","year":"2013","journal-title":"N Am J Med Sci"},{"key":"2022020214134257000_onco13801-bib-0054","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.anndiagpath.2015.02.008","article-title":"Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma","volume":"19","author":"O'Malley","year":"2015","journal-title":"Ann Diagn Pathol"},{"key":"2022020214134257000_onco13801-bib-0055","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/PAS.0000000000000678","article-title":"Spindle cell melanoma and interdigitating dendritic cell sarcoma: Do they represent the same process?","volume":"40","author":"Stowman","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2022020214134257000_onco13801-bib-0056","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1182\/blood-2007-11-124792","article-title":"Clonally related follicular lymphomas and histiocytic\/dendritic cell sarcomas: Evidence for transdifferentiation of the follicular lymphoma clone","volume":"111","author":"Feldman","year":"2008","journal-title":"Blood"},{"key":"2022020214134257000_onco13801-bib-0057","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3324\/haematol.2009.021212","article-title":"Common clonal origin of an acute b-lymphoblastic leukemia and a langerhans\u2019 cell sarcoma: Evidence for hematopoietic plasticity","volume":"95","author":"Ratei","year":"2010","journal-title":"Haematologica"},{"key":"2022020214134257000_onco13801-bib-0058","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/modpathol.2011.102","article-title":"Clonally related histiocytic\/dendritic cell sarcoma and chronic lymphocytic leukemia\/small lymphocytic lymphoma: A study of seven cases","volume":"24","author":"Shao","year":"2011","journal-title":"Mod Pathol"},{"key":"2022020214134257000_onco13801-bib-0059","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/cjp2.177","article-title":"Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation","volume":"7","author":"Kemps","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"2022020214134257000_onco13801-bib-0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","article-title":"Transformed follicular non-Hodgkin lymphoma","volume":"125","author":"Casulo","year":"2015","journal-title":"Blood"},{"key":"2022020214134257000_onco13801-bib-0061","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13801","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/e1263\/42367288\/oncolo_26_7_e1263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/e1263\/42367288\/oncolo_26_7_e1263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T11:59:42Z","timestamp":1724932782000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/7\/e1263\/6510483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,5,6]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13801","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,5,6]]}}}